The rapid screening and isolation of single leukemia cells from blood has become critical for early leukemia detection and tumor heterogeneity interrogation. However, due to the size overlap between leukemia cells and the more abundant white blood cells (WBCs), the isolation and I dentification of leukemia cells individually from peripheral blood is extremely challenging and often requires immunolabeling or cytogenetic assays. Here we present a rapid and label-free single leukemia cell identification platform that combines: (1) high-throughput size-based separation of hemocytes via a single-cell trapping array, and (2) 
Introduction
Leukemia, a group of blood cancers that are characterized by the uncontrolled production of abnormal leukocytes from the bone marrow, is the most prevalent pediatric cancer, 1, 2 and the sixth most common cause of cancer deaths in the U.S. 3 Currently, bone marrow aspiration and biopsy are used commonly as standardized procedures for the diagnosis of leukemia and other blood disorders. However, these methods are usually invasive, risky, and difficult for repeat sample acquisitions over an extended time period 4 . Blood-based detection is gentle in comparison and complete blood count (CBC) and peripheral blood smear are relatively quick.
Although selective biomarker immunostaining and cytogenetic analysis are able to determine the specific types of leukemia, the procedures are complicated, time-consuming, and expensive. [5] [6] [7] There is a critical need in leukemia diagnostics to be able to rapidly and non-invasively isolate single migratory leukemia cells with high sensitivity from unprocessed patient blood samples.
Microfluidic technology is a powerful tool to process blood samples and isolate circulating tumor cells (CTCs) and leukemia cells in a high-throughput, low cost, and portable manner. In fact, a variety of high-performance microfluidic platforms have been established for isolation and enrichment of CTCs from blood as liquid biopsy, including inertial separation 8 , surface acoustic waves, 9 dielectrophoretic sorting 10 and deterministic chromatography 11 . These techniques are particularly powerful when CTCs have apparent larger diameter than white blood cells (WBCs). However, in the case of separating leukemia cells from blood, the low purity of recovered leukemia cells remains a significant challenge because the size of leukemia cells may exhibit overlap with the size of leukocytes. 12 One approach to improve the selectivity is deformability-based microfluidic discrimination of cancer cells 13, 14 , which results in higherperformance cancer cell capture from background cells despite their approximately identical size.
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In these approaches, however, the strong deformations may damage certain cancer cells due to the high shear stress, and the separation of cells through microstructured constrictions is limited by clogging, which reduces selectivity of cancer cells. Alternatively, cancer cells can be sorted based on epithelial cell surface markers expressed predominantly on cancer cells, such as epithelial cell adhesion molecule (EpCAM). However, the capture efficiency would be heavily dependent on the EpCAM expression level of cancer types and patients. 15, 16 Also, recovery of biomarker-conjugated cells from the antibody-coated surface induces leukemia cell damage and requires an additional non-trivial step for culture and enumeration. 17 Jackson and Li et al.
separated the peripheral blood to search for circulating leukemic cells 18 and lymphoblasts 19 within the antibody-immobilized microfluidic channel, respectively, but still needed a timeconsuming labeling process and have typically yielded low sample purities (<1%), causing challenges in downstream analysis.
To overcome these difficulties of the discrimination and isolation of leukemia cells, the development of label-free technologies to identify and discriminate leukemia cells at a single-cell level has become critical for improving leukemia diagnosis. 20, 21 The intrinsic fluorescence of cells generated from endogenous proteins and metabolites is an alternative way to discriminate the cancer cells from normal differentiated cells. The widespread adoption of multiphoton fluorescence imaging and microscopy has followed progressive improvements in label-free and non-invasive detection of cellular metabolism and functional analysis with minimal photodamage and maximized resolution. For example, the reduced form of nicotinamide adenine dinucleotide (NADH) is one of the main fluorescent metabolic coenzymes involved in oxidative phosphorylation (OXPHOS) and glycolysis, reporting metabolic changes associated with cell carcinogenesis and differentiation. Based on the Warburg effect, tumor cells exhibit increased production of lactate because of an increased rate of glycolysis, in which 22 a large population of (Fig. 1a) . 25 26 to compare between the two spectra comprised of the phasor histogram and distribution calculated from leukemia and normal WBCs for quantitative separation and statistical calculation. To the best of our knowledge, the presented platform is the first to enable high-density single-cell trapping simultaneously with RBC filtering and to achieve rapid label-free screening of single leukemia cells through non-invasive metabolic imaging. Compared to conventional biochemical or biomolecular-based diagnostics, the phasor-FLIM based screening opens up new opportunities of using metabolic imaging for in-vitro diagnostics, which overcomes the limitation of complicated sample processing, high-cost, and cytotoxicity. µm, respectively, while the width and length of the traps were both 10 µm.
Cell culture
THP-1 (human acute monocytic leukemia cell line), Jurkat (human acute T cell leukemia cell line), and K562 (human chronic myelogenous leukemia cell line) cells were purchased from American Type Culture Collection (ATCC), and cultured in RPMI1640 medium (Gibco)
supplemented with 10% fetal bovine serum (FBS; Gibco). In particular, for THP-1 cells, 0.05 mM 2-mercaptoethanol (Sigma) was added as a metabolic supplement. Cells were passaged every 2-3 days following standard protocols and cultured in a humidified incubator at 37 °C with 5% CO 2 .
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Blood Samples
De-identified healthy male blood sample was obtained from the Institute for Clinical and Translational Science, Irvine. Vacutainer tubes (BD Bioscience) containing EDTA as an anticoagulant were used for collection. The blood sample was diluted to 2% hematocrit by adding 1× phosphate buffered saline (PBS) (Life Technologies).
Instrument set-up for imaging
Fluorescence lifetime images of the WBC/leukemia single-cell arrays were acquired utilizing a Zeiss LSM710 microscope coupled with a Ti:Sapphire laser system (Mai Tai Spectra-Physics, Newport, CA) and an ISS A320 FastFLIM unit (ISS, Champaign, IL). SimFCS software, developed at the Laboratory of Fluorescence Dynamics (LFD), University of California, Irvine, was used to control the system for FLIM data acquisition. The single-cell array was placed in the
Results
Design and operating principle of the platform
The presented high-density single-cell array consists of a serpentine-shape microfluidic channel with size-selective traps arrayed along each row, by which single WBCs and leukemia cells are captured passively with RBCs filtered out simultaneously due to their smaller size (Fig. 1b) Most of the normal WBCs and leukemia cells have a diameter ranging from 8 µm to 20 µm, and there exist significant size overlap based on our measurement of normal human WBCs, and three different types of leukemia cells: THP-1, Jurkat, and K562 (Fig. 2a) we chose an optimal h g ~ 3.3 µm to operate a device for WBC isolation applications. Fig. 2c shows that the bright-field microscopic image of trapping WBCs and leukemia cells (K562)
within the microwell arrays with h g = 3.3 µm. After turning off the sample flow and introducing (Fig. 2e and 2f, Supporting materials, Fig. S2 ). We chose to introduce 2% hematocrit blood under 0.2 mL/h for implementing both the throughput and the single-cell isolation performance.
Phasor-FLIM measurement of WBC and leukemia single-cell arrays
Single cells of 4 different populations, WBC (Fig. 3a) , THP-1 (Fig. 3b) , Jurkat ( and K562) were located closely in the scatter plot, they can still be quantitatively differentiated by a multiparametric analysis, or distance analysis 26, 29 , that splits every cell's phasor points in four equidistance segments based on the height/intensity of the 3D phasor distribution and calculates the average coordinates (g and s) in each segment (Fig. S3) . A spectrum of 8 parameters specific to the phasor distribution of each cell is created based on the above, and quantitative separation can be applied to the spectra of two different groups, the control (C) and the test (T). The average spectrum of each group and the deviation of each member from the (Fig. 4b) . Importantly, this classification is performed at a single-cell level rather than as a population metric and across three samples. This multiprapmeteric analysis can also be adopted to broadly separate WBCs from leukemia cells. In Fig. 4c , WBCs are considered as the C group, and all three types of leukemia cells are the T group. While the SI of T group is broadly distributed, indicating the heterogeneity of the leukemia cell population, there is no overlap with the SI distribution of WBCs, and the AUC = 1.000, which means that leukemia cell lines can be clearly differentiated from WBCs based on the multiparameter scheme, confirming the scatter plot in Fig. 3e (Fig. 4d ).
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Rapid single leukemia cell screening from leukemia-cell-spiked blood samples via phasor-
FLIM imaging of the high-density trapping array
After identification of the difference in the phasor-FLIM fingerprints of single WBCs and leukemia cell lines (THP-1, Jurkat, and K562), we conducted the rapid label-free single leukemia cell screening in leukemia-cell-spiked human blood samples. THP-1, Jurkat, and K562 cells were spiked into human blood at a 1 to 5 ratio to WBCs, separately, in order to mimic the blood sample of patients with different types of leukemia, and the diluted whole blood samples (2% hematocrit) were introduced into the high-density single-cell arrays under the flow rate of 0.3 mL/h ( Fig. 5(i) ). Then we collected the NADH fluorescence emission of trapped single cells ( Fig. 5 (ii)) and fluorescence lifetime data at 740 nm, two-photon excitation and plotted the lifetime maps ( Fig. 5(iii) ) by 1) linking the higher bound/free-NADH-ratio group (red cursor) and the higher free/bound-NADH-ratio group (green cursor) in the phasor distribution plot of all the trapped single cells (Fig. 5d) , and 2) color-coding: the color scale from white/cyan to red/pink represents a linear increase of free to protein-bound NADH ratio (Fig. 5e) . 32 (Fig. 4b) . As the FLIM data collection of each laser scanning area containing 100 single-cell traps takes less than 1 min, the leukemia cell screening of the total 1,600 traps could be achieved within 16 mins. glycolysis. Also, quantitative separation is achieved (Fig. 4) based on the multiparameter scheme comparing the 8 parameter-spectra of the phasor-FLIM distributions. Both of the above demonstrate that phasor-FLIM based screening is a label-free and robust leukemia cell identification approach, and our platform is the first demonstration to discriminate single leukemia cells from WBCs using phasor-FLIM based on the difference of free/bound NADH ratio. This platform could potentially be useful for discrimination of single activated and nonactivated T cells because recent work claims that the Warburg effect is a key process that assist T cell survival and proliferation after activation, as well as produce the effector cytokines. 33 The stimulation of CD8+ T cells boosts rapid production of ROS which has its unique fluorescence lifetime signature in the bottom-left portion of the phasor plot. 34, 35 In addition, the activated T cells express a functional phagocyte-type NADPH oxidase, which would shift the FLIM signature towards longer lifetime range. 36 Both of the two aspects lead to a more complex change in FLIM signatures during T cell activation, and should be different from that of tumor cells, which simply shifts towards the shorter lifetime caused by glycolysis.There have been substantial research reporting that leukemic cells are highly glycolytic even though cells reside within the bloodstream which has higher oxygen tension than cells in most normal tissues. 37, 38 To expedite leukemia detection and improve personalized therapies, it is crucial to quickly screen the abnormal leukocytes that might allow determination of effective treatment to be made Intra-population heterogeneity were also observed through the cell-cell variation of phasor-FLIM signatures. Our platform is the first to enable high-density single-cell trapping simultaneously with RBC filtering and to achieve rapid label-free individual-leukemia-cell screening through non-invasive metabolic imaging. Phasor-FLIM based screening on a high-density trapping array is label-free, cell-safe, quantitative, and it has the potential to screen blood in clinical volumes through parallelization and is expected to be widely used regarding early leukemia/tumor detection, tumor heterogeneity identification, and personalized therapy. 
